InsidersTradesSigma
Track the Phoenix Biotech Acquisition CORP. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Phoenix Biotech Acquisition CORP. has logged 3 reports. The latest transaction was filed on 12 October 2021 (J). Among the most active insiders: PHOENIX BIOTECH SPONSOR, LLC. The full history is openly available.
3
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
30Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 12 October 2021
Declarations3 total
36,733 shares@ US$10.00100.0% of flowClass A common stockSEC:0000899243-21-039943:0
36,733 shares@ US$10.00100.0% of flowClass A common stockSEC:0000899243-21-039941:0
10,000 sharesClass A common stockSEC:0000899243-21-039936:0
3 of 3 declarations
关于 Phoenix Biotech Acquisition CORP.
Phoenix Biotech Acquisition Corp.是一家在美国纽约证券交易所/纳斯达克生态系统上市的公司，最初是一家特殊目的收购公司（SPAC）。它于2021年6月8日在特拉华州注册成立，旨在通过合并、股份交换、资产收购、股权购买、重组或与一个或多个目标业务进行类似的业务合并。在其发行文件中，该公司表示打算将搜索重点放在美国和欧洲的医疗保健及相关行业。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1870404/000119312521271453/d198272ds1.htm?utm_source=openai)) 从地理角度来看，Phoenix Biotech Acquisition Corp.最初披露的地址是加利福尼亚州奥克兰，而随后的交易和合并后文件则提及加利福尼亚州南旧金山，这突显了其靠近美国最重要的生物技术集群之一。对于投资者而言，关键点在于这并非一家在成立之初就拥有多元化收入来源的传统运营公司；相反，它是一个上市的资本市场工具，旨在将医疗保健或生物技术业务推向公开市场。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1870404/000121390023053961/ea181281ex99-1_phoenix.htm?utm_source=openai)) 最近的决定性进展是与CERo Therapeutics的业务合并，该合并于2023年6月宣布，并于2024年2月完成。CERo是一家免疫治疗公司，专注于利用吞噬机制的下一代工程T细胞疗法。合并完成后，Phoenix Biotech Acquisition Corp.有效地成为合并后公司的上市载体，市场身份转向CERo及其CERO股票代码。此次交易是公司最重要的里程碑，并解释了当前的投资案例。（[businesswire.com](https://www.businesswire.com/news/home/20230603005013/en/CERo-Therapeutics-Inc.-and-Phoenix-Biotech-Acquisition-Corp.-Announce-Merger-Agreement-to-Create-Public-Company-Advancing-the-Development-of-Next-Generation-Engineered-T-Cell-Therapeutics?utm_source=openai)) 在竞争方面，这个故事更多地关乎进入公开股权市场、临床开发执行以及底层生物技术平台的质量，而非历史运营规模。免疫治疗领域竞争激烈、资本密集且受到严格监管，因此公司的未来业绩主要取决于科学进展、临床数据生成、监管里程碑和融资能力。与许多SPAC起源的交易一样，投资者还应关注交易时机、结构变化以及合并后整合或上市相关要求。（[businesswire.com](https://www.businesswire.com/news/home/20230603005013/en/CERo-Therapeutics-Inc.-and-Phoenix-Biotech-Acquisition-Corp.-Announce-Merger-Agreement-to-Create-Public-Company-Advancing-the-Development-of-Next-Generation-Engineered-T-Cell-Therapeutics?utm_source=openai)) 总的来说，Phoenix Biotech Acquisition Corp.最好被理解为一个美国纽约证券交易所/纳斯达克上市的SPAC平台，通过CERo Therapeutics转型为一家公开上市的生物技术公司，其业务足迹位于加利福尼亚州，其价值主张现在与免疫治疗开发而非传统运营相关联。（[businesswire.com](https://www.businesswire.com/news/home/20240214145586/en/Phoenix-Biotech-Acquisition-Corp.-and-CERo-Therapeutics-Inc.-Announce-Close-of-Business-Combination?utm_source=openai))
